Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Shares Outstanding (Diluted Average) (2020 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Shares Outstanding (Diluted Average) for 9 consecutive years, with $22.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 5.46% to $22.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.4 million, a 5.46% increase, with the full-year FY2025 number at $22.4 million, up 5.46% from a year prior.
  • Shares Outstanding (Diluted Average) was $22.4 million for Q4 2025 at Madrigal Pharmaceuticals, up from $22.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $22.4 million in Q4 2025 to a low of $15.8 million in Q1 2021.
  • A 5-year average of $19.0 million and a median of $18.3 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 2.79% in 2022, then grew 17.28% in 2024.
  • Madrigal Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $16.5 million in 2021, then increased by 3.64% to $17.1 million in 2022, then grew by 9.05% to $18.7 million in 2023, then rose by 13.83% to $21.3 million in 2024, then rose by 5.46% to $22.4 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Shares Outstanding (Diluted Average) are $22.4 million (Q4 2025), $22.3 million (Q3 2025), and $22.2 million (Q2 2025).